Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13622779 | 1.00 | PER2 (0.40) | PER2CRY2 | |
| SCHEMBL8045418 | 0.78 | PIK3CD (0.46) | PER2CRY2 | |
| SCHEMBL8282110 | 0.77 | SMN1; SMN2 (0.38) | PER2CRY2 | |
| SCHEMBL13622786 | 0.76 | PIK3CD (0.55) | PER2CRY2 | |
| SCHEMBL8282119 | 0.76 | PIK3CD (0.55) | PER2CRY2 | |
| SCHEMBL8239916 | 0.74 | PER2 (0.44) | PER2CRY2 | |
| SCHEMBL13804490 | 0.72 | PER2 (0.42) | PER2CRY2 | |
| SCHEMBL8284333 | 0.71 | PIK3CD (0.55) | PER2CRY2 | |
| SCHEMBL13792612 | 0.71 | PER2 (0.41) | PER2CRY2 | |
| SCHEMBL8051770 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730142-B1 | NOVEL KETOAMIDES WITH CYCLIC P4'S AS INHIBITORS OF NS3 SERINE PROTEASE OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2011-06-29 | — | — | EP | disclosed |
| US-7619094-B2 | Ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | SCHERING CORPORATION (US) | 2009-11-17 | — | — | US | disclosed |
| US-7173057-B2 | Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus | SCHERING CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
| WO-2005085242-A1 | NOVEL KETOAMIDES WITH CYCLIC P4'S AS INHIBITORS OF NS3 SERINE PROTEASE OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |